1、 2025.All rights reserved.IQVIA is a registered trademark of IQVIA Inc.in the United States,the European Union,and various other countries.Published April 2025EFPIA Patients W.A.I.T.Indicator 2024 SurveyMax Newton,Principal,Strategic Partners(GS&AR)Kelsey Stoddart,Sr Consultant,Global Supplier&Assoc

2、iation RelationsMarco Travaglio,Consultant,Global Supplier&Association RelationsPer Troein,VP,Strategic Partners1Indicators measure availability,restrictions to availability and time to availabilityForewordThe Patients W.A.I.T.(Waiting to Access Innovative Therapies)Indicator has been running in evo

3、lving formats since 2004 and has offered a comprehensive overview of public reimbursement across over 30 countries since 2018.However,the relevance of whether an innovative molecule is included on public reimbursement lists has diminished over the years,with a rise in patient access through alternat

4、ive channels and/or with restrictions.This years iteration of the report retains the core availability metrics,whilst adding additional context around the positioning of the report within the broader access landscape,and greater granularity on the level of restrictions to patient access(i.e.individu

5、al patient only).These updates aim to ensure the report remains relevant in new access landscape and support the accurate use of the W.A.I.T.report.Information on the availability of 173 innovative medicines with central-marketing authorisation between 2020 and 2023 are included in the report.There

6、is a one-year delay to permit countries to include these medicines on their public reimbursement list,meaning that the data on availability is accurate as of January 5th 2025.Local pharmaceutical industry associations provide the information directly to IQVIA and EFPIA,and their definitions are incl